New Research Reports

We recently met with Coforge’s management to discuss the company’s outlook on growth, margins, and cash flow conversion.

Emami's performance in 1Q FY26 was impacted by external factors like
unseasonal weather which particularly affected its summer-focused portfolio.
Despite these challenges, the company's core domestic business, excluding
talc, demonstrated resilience with a 6% y-o-y revenue growth.

Quarterly Update Q1FY26

We recently upgraded PLNG to BUY (Tide is turning, slowly) on inexpensive valuations and strong upcoming capacity growth.

ee costs (+11.2% YoY) and other operating expenses (+25.2% YoY). Net profit grew 3.2% YoY to Rs. 530cr, as tax expenses came down by 5.5% YoY. Gross stage 3 (GS3) ratio increased from 3.56% in Q1FY25 to 3.85% in Q1FY26,...

Star Health (STARHEAL) has reported lower growth than its SAHI peers, which has led to market share loss for the company in the health segment to 11.4% (YTDFY26) vs. 15.7% in FY21.

PVC pipe demand is expected to rebound from Q2FY26 after a subdued start in Q1, which was hit by declining PVC prices, early monsoons, lower government spending and inventory losses.

Order pipeline remains robust; longer-term growth outlook intact: Order pipeline also remains strong for the company, considering the opportunities from both defence & commercial segments. Contracts like additional three Kalvari class submarines (expected order size Rs 3000040000 crore) and six next-generation submarines under P-75I (expected value ~Rs 70000 crore) have already been cleared from govt and expected to be placed with the company in near to medium term. Following this, other major contracts like next-generation corvettes (expected value ~Rs 36000 crore), next-generation frigates or P-17B (expected value ~Rs...

*over or under performance to benchmark index Godrej Properties Ltd (GPL) is a real estate company, with its head office in Mumbai, India. The company is a subsidiary of Godrej Industries Ltd and was established in...

We have revised our FY26E/FY27E EPS estimates by -4.4%/-9.0% factoring in a miss in Q1FY26 performance, slower-than-expected recovery in exports due to prolonged customer destocking, and regulatory headwinds in biologicals that have curtailed domestic growth.